No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EHC Encompass Health
- 82.585
- -0.145-0.18%
Trading Apr 26 11:25 ET
8.27BMarket Cap22.32P/E (TTM)
83.050High82.320Low178.37KVolume82.620Open82.730Pre Close14.76MTurnover0.18%Turnover Ratio23.80P/E (Static)100.14MShares85.84052wk High4.75P/B8.15BFloat Cap57.30952wk Low0.60Dividend TTM98.72MShs Float85.840Historical High0.73%Div YieldTTM0.88%Amplitude0.071Historical Low82.733Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Is Encompass Health Corporation (NYSE:EHC) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, Encompass Health fair value estimate is US$65.49 Encompass Health is estimated to be 26% overvalued based on current share price of US$82.73
Express News | Encompass Health Corp : Raymond James Raises Target Price to $95 From $85
Results: Encompass Health Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates
Encompass Health Corp (EHC) Q1 2024 Earnings Call Transcript Highlights: Strong Performance and ...
Earnings Call Summary | Encompass Health(EHC.US) Q1 2024 Earnings Conference
The following is a summary of the Encompass Health Corporation (EHC) Q1 2024 Earnings Call Transcript:Financial Performance:Encompass Health reported a revenue growth of 13.4% and adjusted EBITDA incr
Encompass Health Is Maintained at Overweight by Barclays
Encompass Health Is Maintained at Overweight by Barclays
Comments
Insiders selling shares below the current price could indicate their belief in the fairness of the lower price and skepticism about the higher valuation. However, the reasons for selling are varied and unknown. The level of insider ownership suggests some alignment with other shareholders.
Encompass Health Insider Lowered Holding By 26% During Last YearDespite solid earnings growth, the company's high P/E ratio is concerning given its lower forecast growth. Investors remain bullish, but the earnings growth may not sustain the share price. The high P/E ratio may not support the positive sentiment for long.
Encompass Health may be undervalued according to metrics, hinting a buying opportunity. The company's positive growth outlook isn't fully incorporated in its current share price. Considering management's track record is advised before investment.
Despite significant insider ownership possibly aligning company operations to all shareholders' interests, lack of insider buying over the past year is cautionary. Share sales at current trading prices could further induce wariness.
The company has shown similar rates of growth in EPS and share price, giving evidence that market perception of Encompass Health hasn't markedly changed. Considering the strong momentum in share price, it may be valuable to examine the stock further.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg